- Home
- / Panacea Biotec
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Panacea Biotec financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₹156.6
2023-11-30
Market Capitalization
₹9.7 B
2023-11-30
Revenue
₹4.6 B
FY, 2023
CreditSafe Score
?
Score changed on Dec 06, 2023
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 5.7B | 4.5B | 5.4B | 6.2B | 6.6B | 4.6B |
| Cost of goods sold | 2.1B | 2.0B | 1.7B | 2.3B | 3.0B | 2.8B |
| Gross profit | 3.9B | 2.6B | 3.7B | 4.0B | 3.7B | 1.9B |
| Gross profit margin, % | 67.9% | 57.7% | 69.4% | 64.8% | 55.5% | 40.6% |
| Operating expense total | 2.9B | 3.7B | 3.1B | 3.1B | 3.7B | 2.8B |
| Depreciation and amortization | 585.3M | 540.0M | 441.4M | 500.7M | 444.4M | 391.2M |
| EBITDA | 995.3M | (1.1B) | 808.6M | 901.6M | (52.0M) | (652.2M) |
| EBITDA margin, % | 17.4% | -24.6% | 15.1% | 14.6% | -0.8% | -14.3% |
| EBIT | 386.1M | 1.7B | 213.3M | 400.9M | 16.3B | (16.8M) |
| EBIT margin, % | 6.7% | 37.3% | 4.0% | 6.5% | 246.7% | -0.4% |
| Interest income | 11.7M | 6.8M | 47.9M | 32.7M | 33.9M | 115.6M |
| Interest expense | 1.0B | 1.0B | 1.7B | 1.9B | 1.8B | 44.4M |
| Pre tax profit | (661.4M) | 486.2M | (1.8B) | (1.5B) | 14.5B | 128.1M |
| Income tax expense | 98.6M | 77.1M | 169.5M | 26.3M | 3.7B | 465.5M |
| Net Income | (760.0M) | 409.1M | (1.9B) | (1.5B) | 10.8B | (337.4M) |